Please assess the completion status of the following clinical trial:

Trial Title: Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All adults with established, pathologically confirmed diagnoses of newly diagnosed AML and adults with newly diagnosed AML, excluding newly diagnosed core-binding factor (CBF) AMLs and acute progranulocytic leukemia (APL, M3), will be considered eligible for study~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3~  * Patients \>= 65 years of age must have ECOG PS =\< 2 prior to developing leukemic symptoms~* Serum creatinine ≤ 2.0 mg/dL~* Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =\< 5 times upper limit of normal (ULN) (unless leukemic infiltration)~* Total bilirubin =\< 2.0 mg/dL (unless Gilbert disease, hemolysis, or leukemia)~* Left ventricular ejection fraction ≥ 45%~* Newly diagnosed AML, subtypes M0, 1, 2, 4-7 but excluding M3 (APL), including those with the following poor risk features:~  * Antecedent hematologic disorder including myelodysplasia (MDS)-related AML (MDS/AML) and prior myeloproliferative disorder (MPD)~ * Treatment-related myeloid neoplasms (t-AML/t-MDS)~ * Myeloid sarcoma, myeloid proliferations related to Down Syndrome, and blastic plasmacytoid dendritic cell neoplasm~ * AML with multilineage dysplasia (AML-MLD)~ * Adverse cytogenetics (defined as -5/-5q; -7/-7q; abnormal 3q, 9q, 11q, 20q, 21q, or 17p; t(6;9); t(9;22); trisomy 8; trisomy 13; trisomy 21; and complex karyotypes (≥ 3 unrelated abnormalities)~* Patients who have received hydroxyurea alone or have received non-cytotoxic therapies previously for myelodysplasia (MDS) or myeloproliferative disorder (MPD) (e.g., thalidomide or lenalidomide, interferon, cytokines, 5-azacytidine or decitabine, histone deacetylase inhibitors, low-dose cyclophosphamide \[cytoxan\], tyrosine kinase \[TK\] or dual TK/src inhibitors) will be eligible for this trial~  * At least 24 hours since prior leukopheresis or hydroxyurea for cytoreduction~Exclusion Criteria:~* Any previous treatment with flavopiridol~* Concomitant chemotherapy, radiation therapy, or immunotherapy~* Hyperleukocytosis with \>= 50,000 blasts/uL; leukopheresis or hydroxyurea may be used immediately prior to study drug administration for cytoreduction; must be stopped 24 hours before first dose of study chemotherapy~* CBF AMLs associated with t(8;21) or M4eo subtype (inv\[16\] or t\[16;16\]), as diagnosed by morphologic criteria, flow cytometric characteristics, and rapid cytogenetics or FISH or molecular testing~* Acute Progranulocytic Leukemia (APL, M3)~* Active central nervous system (CNS) leukemia~* Active, uncontrolled infection; patients with infection under active treatment and controlled with antibiotics are eligible~* Active, uncontrolled graft vs. host disease (GVHD) following allogeneic transplant for non-AML condition (e.g. MDS, lymphoid malignancy, aplastic anemia); patients with GVHD controlled on stable doses of immunosuppressants are eligible~* Presence of other life-threatening illness~* Patients with mental deficits and/or psychiatric history that preclude them form giving informed consent or from following protocol~* Pregnant and nursing patients are excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (alvocidib, cytarabine, mitoxantrone hydrochloride) (Type: EXPERIMENTAL): Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Patients who achieve complete or partial response to the first course (completion of all doses) may receive a second course of treatment or high-dose cytarabine after 21-63 days following blood count recovery, and/or undergo allogeneic bone marrow transplant.
- Arm II (cytarabine, daunorubicin hydrochloride) (Type: ACTIVE_COMPARATOR): Patients receive cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients who have residual disease on day 14 may receive additional cytarabine for 5 days and daunorubicin hydrochloride for 2 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).